共 140 条
[1]
Cross M(2014)The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study Ann Rheum Dis 73 1316-1322
[2]
Smith E(2011)Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data Pharmacoepidemiol Drug Saf 20 119-130
[3]
Hoy D(2009)The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events Ann Rheum Dis 68 1136-1145
[4]
Carmona L(2012)Cancer risk of anti-TNF-alpha at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses PLoS One 7 149-156
[5]
Wolfe F(2017)Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis Semin Arthritis Rheum 47 1895-1904
[6]
Vos T(2011)Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis Ann Rheum Dis 70 2886-2895
[7]
Williams B(2007)Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study Arthritis Rheum 56 756-764
[8]
Gabriel S(2012)Risk of malignancy including non-melanoma skin cancers with anti-tumor necrosis factor therapy in patients with rheumatoid arthritis: meta-analysis of registries and systematic review of long-term extension studies Clin Exp Rheumatol 30 e3-e42
[9]
Lassere M(2019)The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis Rheumatology (Oxford) 58 i262-874
[10]
Johns N(2016)Rheumatoid arthritis, anti-tumour necrosis factor treatment, and risk of squamous cell and basal cell skin cancer: cohort study based on nationwide prospectively recorded data from Sweden BMJ. 352 869-2012